Free Webex Call
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
FEATURED COMPANIES
- Abbexa
- Amgen
- Jena Biosciences
- Nippon Gene
- Promega
- Takara Bio
Free Webex Call
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Restriction Endonuclease Market is expected to grow at a formidable CAGR during the forecast period. The key factor responsible for the market growth is growing investment in research and development activities in end-use industries such as the biotechnology sector and pharmaceutical industry. Additionally, rising incidences of chronic health disorders like diabetes, cancer among others is anticipated to bode well for the growth of the restriction endonuclease market across the globe in the coming years. Moreover, increasing government support in terms of providing funds is projected to bolster the market growth through 2025.
The Global Restriction Endonuclease Market is segmented based on type, application, end-type, source, cleavage, end-user, region and company. Based on type, the market can be segmented into Type I, Type II, Type III and Type IV. Out of which, the Type II segment dominated the market in terms of largest market size until 2019 and is further anticipated to maintain its lead during the forecast years as well. This growth can be accredited to its use in molecular biology applications that are carried on everyday such as gene cloning and DNA fragmentation and analysis. Also, because these enzymes cleave DNA at fixed positions, therefore small, well-defined fragments of DNA are produced which assist in characterization of genes and genomes, thereby anticipated to boost the growth of Type II restriction endonucleases segment over the coming years. Moreover, increasing investments in development activities by biotechnology companies is further aiding the segmental growth.
Major players operating in the Global Restriction Endonuclease Market include New England Biolabs, Thermo Fisher Scientific, Takara Bio, Sigma-Aldrich, Illumina, Agilent Technologies, Promega, Jena Biosciences, Genetix Biotech Asia Pvt. Ltd., Roche, Merck, Pfizer, Amgen, Vertex Pharmaceuticals, BioMarin Pharmaceutical, PerkinElmer, Abcam, Abbexa, Sisco Research Laboratories Pvt Ltd, Nippon Gene. The companies operating in the restriction endonuclease market across the globe are focussing more towards the expanding their share in the market. For instance, these key players are making organic strategies such as developing novel technologies in order to meet the requirements of users and to make the industry highly competitive.
Years considered for this report:
Objective of the Study:
The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of companies across the globe. Subsequently, researchers conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the companies which could not be identified due to the limitations of secondary research. The author analyzed the new products, distribution channels and presence of all major players across the globe.
The author calculated the market size of the Global Restriction Endonuclease Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. They sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.
Report Scope:
In this report, the Global Restriction Endonuclease Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Market, By Type:
Market, By Application:
Market, By End-Type:
Market, By Source:
Market, By Cleavage Specificity:
Market, By End-User:
Market, By Region:
Competitive Landscape
Available Customizations:
With the given market data, researchers offers customizations according to a company’s specific needs.
The Global Restriction Endonuclease Market is segmented based on type, application, end-type, source, cleavage, end-user, region and company. Based on type, the market can be segmented into Type I, Type II, Type III and Type IV. Out of which, the Type II segment dominated the market in terms of largest market size until 2019 and is further anticipated to maintain its lead during the forecast years as well. This growth can be accredited to its use in molecular biology applications that are carried on everyday such as gene cloning and DNA fragmentation and analysis. Also, because these enzymes cleave DNA at fixed positions, therefore small, well-defined fragments of DNA are produced which assist in characterization of genes and genomes, thereby anticipated to boost the growth of Type II restriction endonucleases segment over the coming years. Moreover, increasing investments in development activities by biotechnology companies is further aiding the segmental growth.
Major players operating in the Global Restriction Endonuclease Market include New England Biolabs, Thermo Fisher Scientific, Takara Bio, Sigma-Aldrich, Illumina, Agilent Technologies, Promega, Jena Biosciences, Genetix Biotech Asia Pvt. Ltd., Roche, Merck, Pfizer, Amgen, Vertex Pharmaceuticals, BioMarin Pharmaceutical, PerkinElmer, Abcam, Abbexa, Sisco Research Laboratories Pvt Ltd, Nippon Gene. The companies operating in the restriction endonuclease market across the globe are focussing more towards the expanding their share in the market. For instance, these key players are making organic strategies such as developing novel technologies in order to meet the requirements of users and to make the industry highly competitive.
Years considered for this report:
- Historical Years: 2015-2018
- Base Year: 2019
- Estimated Year: 2020
- Forecast Period: 2021–2025
Objective of the Study:
- To analyse and forecast the market size of the Global Restriction Endonuclease Market.
- To classify and forecast the Global Restriction Endonuclease Market based on type, application, end type, source, cleavage, end-user, company and regional distribution.
- To identify drivers and challenges for the Global Restriction Endonuclease Market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Restriction Endonuclease Market.
- To conduct pricing analysis for the Global Restriction Endonuclease Market.
- To identify and analyse the profile of leading players operating in the Global Restriction Endonuclease Market.
The author performed both primary as well as exhaustive secondary research for this study. Initially, researchers sourced a list of companies across the globe. Subsequently, researchers conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, researchers could include the companies which could not be identified due to the limitations of secondary research. The author analyzed the new products, distribution channels and presence of all major players across the globe.
The author calculated the market size of the Global Restriction Endonuclease Market by using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. They sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Restriction endonuclease companies and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums and alliances related to restriction endonuclease
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies and partners, end-users, etc., besides allowing them in strategizing investments and capitalizing on the market opportunities.
Report Scope:
In this report, the Global Restriction Endonuclease Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Market, By Type:
- Type I
- Type II
- Type III
- Type IV
Market, By Application:
- Genetic Engineering
- DNA Mapping
- Gene Sequencing
- Others
Market, By End-Type:
- Sticky End
- Blunt End
Market, By Source:
- Bacteria
- Archaea
Market, By Cleavage Specificity:
- Isoschizomers
- Neoschizomers
Market, By End-User:
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Others
Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Singapore
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- South America
- Brazil
- Argentina
- Colombia
Competitive Landscape
- Company Profiles: Detailed analysis of the major companies present in the Global Restriction Endonuclease Market.
Available Customizations:
With the given market data, researchers offers customizations according to a company’s specific needs.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbexa
- Amgen
- Jena Biosciences
- Nippon Gene
- Promega
- Takara Bio
1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Restriction Endonuclease Market4. Executive Summary12. Market Trends & Developments14. Strategic Recommendations15. About Us & Disclaimer
5. Global Restriction Endonuclease Market Outlook
6. Asia-Pacific Restriction Endonuclease Market Outlook
7. Europe Restriction Endonuclease Market Outlook
8. North America Restriction Endonuclease Market Outlook
9. South America Restriction Endonuclease Market Outlook
10. Middle East and Africa Restriction Endonuclease Market Outlook
11. Market Dynamics
13. Competitive Landscape
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- New England Biolabs
- Thermo Fisher Scientific
- Takara Bio
- Sigma-Aldrich
- Illumina
- Agilent Technologies
- Promega
- Jena Biosciences
- Genetix Biotech Asia Pvt. Ltd.
- Roche
- Merck
- Pfizer
- Amgen
- Vertex Pharmaceuticals
- BioMarin Pharmaceutical
- PerkinElmer
- Abcam
- Abbexa
- Sisco Research Laboratories Pvt Ltd
- Nippon Gene
Note: Product cover images may vary from those shown